as 12-17-2024 4:00pm EST
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 134.2M | IPO Year: | N/A |
Target Price: | $111.50 | AVG Volume (30 days): | 12.4M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.37 | EPS Growth: | N/A |
52 Week Low/High: | $2.55 - $42.20 | Next Earning Date: | 11-07-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
SAVA Breaking Stock News: Dive into SAVA Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
Zacks
22 days ago
Zacks
22 days ago
Zacks
22 days ago
MT Newswires
22 days ago
Investor's Business Daily
23 days ago
Yahoo Finance Video
23 days ago
MT Newswires
23 days ago
The information presented on this page, "SAVA Cassava Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.